Applied Health Economics and Health Policy

2008 - 2025

Current editor(s): Timothy Wrightson

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 23, issue 4, 2025

Design Patents: A Potential Threat to Drug Competition pp. 531-534

Janet Freilich and Aaron S. Kesselheim

Alternative Payment Models for Innovative Medicines: A Framework for Effective Implementation pp. 535-549

Frederick McElwee, Amanda Cole, Gomathi Kaliappan, Andrea Masters and Lotte Steuten

The Cost and Cost-Effectiveness of Childbirth Settings: A Systematic Review pp. 551-568

Vanessa Scarf, Habtamu Kasaye, Kate Levett and Emily Callander

Decision-Analytical Modelling of Medicines in the Middle East: A Systematic Review of Economic Evaluation Studies pp. 569-612

Zainab Abdali, Tuba Saygın Avşar, Sue Jowett, Muslim Syed, Khalifa Elmusharaf and Louise Jackson

Compulsory Licensing as an Instrument to Tackle High Medicine Prices: A Realist Review of Industrial and Health Consequences pp. 613-624

Steven Simoens, Walter Dyck, Rosanne Janssens, Liese Barbier and Jeroen Luyten

GaitSmart Rehabilitation Exercise Programme for Gait and Mobility Issues: A NICE Medical Technologies Guidance pp. 625-637

Huey Yi Chong, Michal Pruski, Megan Dale and Rhys Morris

Machine Learning-Assisted Health Economics and Policy Reviews: A Comparative Assessment pp. 639-647

Ludovico Cavallaro, Vittoria Ardito, Michael Drummond and Oriana Ciani

Cost-Effectiveness and Value of Information Analyses of Caplacizumab for the Treatment of Thrombotic Thrombocytopenic Purpura in Brazil pp. 649-660

Julia Simões Correa Galendi, Hannes Rasch, Carlos Antonio Caramori, Rafael Dezen Gaiolla, Dirk Müller and Vania Santos Nunes Nogueira

Predicting Health Utilities Using Health Administrative Data: Leveraging Survey-linked Health Administrative Data from Ontario, Canada pp. 661-677

Yue Niu, Nazire Begen, Guangyong Zou and Sisira Sarma

New Horizons? Assessing General Public Preferences for a Wellbeing Economy in the Post-COVID-19 World pp. 679-691

Rachel Milte, Matthew Crocker, Gang Chen, Gordon Duff and Julie Ratcliffe

Is the Use of Unanchored Matching-Adjusted Indirect Comparison Always Superior to Naïve Indirect Comparison on Survival Outcomes? A Simulation Study pp. 693-704

Ying Liu, Xiaoning He, Jia Liu and Jing Wu

Evaluating Access Improving Interventions: An Economic Evaluation of Surgical Task-Shifting for C-Sections in Sierra Leone pp. 705-723

Bryony Dawkins, Bethany Shinkins, Tim Ensor, David Jayne, Thomas Ashley, Alex J. Duinen, Håkon A. Bolkan and David Meads

A Head-On Comparison of EQ-VT- and Crosswalk-Based EQ-5D-5L Value Sets pp. 725-736

Henry Bailey and Bram Roudijk

Young People’s Preferences for Web-Based Mental Health Interventions for Managing Anxiety and Depression: A Discrete Choice Experiment pp. 737-749

Thi Quynh Anh Ho, Lidia Engel, Jemimah Ride, Long Khanh-Dao Le, Glenn Melvin, Ha N. D. Le and Cathrine Mihalopoulos

Correction: Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases pp. 751-751

Constanza Vargas, Richard Abreu Lourenco, Manuel Espinoza and Stephen Goodall

Correction: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England pp. 753-754

Beth Woods, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Sue Harnan, Jean Hamilton, Alison Scope, Shijie Ren, Laura Bojke, Mark Wilcox, William Hope, Colm Leonard, Philip Howard, David Jenkins, Alan Ashworth, Andrew Bentley and Mark Sculpher

Volume 23, issue 3, 2025

The Health Economics of Genomic Technologies: A Growing Evidence Base on Value pp. 331-335

James Buchanan, Ilias Goranitis and Deirdre Weymann

Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework pp. 337-358

Hadley Stevens Smith, Dean A. Regier, Ilias Goranitis, Mackenzie Bourke, Maarten J. IJzerman, Koen Degeling, Taylor Montgomery, Kathryn A. Phillips, Sarah Wordsworth, James Buchanan and Deborah A. Marshall

The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review pp. 359-393

Mackenzie Bourke, Aideen McInerney-Leo, Julia Steinberg, Tiffany Boughtwood, Vivienne Milch, Anna Laura Ross, Elena Ambrosino, Kim Dalziel, Fanny Franchini, Li Huang, Riccarda Peters, Francisco Santos Gonzalez and Ilias Goranitis

Public Preferences for Genetic and Genomic Risk-Informed Chronic Disease Screening and Early Detection: A Systematic Review of Discrete Choice Experiments pp. 395-408

Amber Salisbury, Joshua Ciardi, Richard Norman, Amelia K. Smit, Anne E. Cust, Cynthia Low, Michael Caruana, Louisa Gordon, Karen Canfell, Julia Steinberg and Alison Pearce

How is Value Defined in Molecular Testing in Cancer? A Scoping Review pp. 409-424

Alice Minhinnick, Francisco Santos-Gonzalez, Michelle Wilson and Paula Lorgelly

Beyond the Diagnosis: Valuing Genome-Wide Sequencing for Rare Disease Diagnosis Using Contingent Valuation pp. 425-439

Michael Abbott, Mandy Ryan, Rodolfo Hernández, Sebastian Heidenreich and Zosia Miedzybrodzka

Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework pp. 441-452

Reka E. Pataky, Stuart Peacock, Stirling Bryan, Mohsen Sadatsafavi and Dean A. Regier

Exome Sequencing in the Diagnostic Pathway for Suspected Rare Genetic Diseases: Does the Order of Testing Affect its Cost-Effectiveness? pp. 453-466

Koen Degeling, Toni Tagimacruz, Karen V. MacDonald, Trevor A. Seeger, Katharine Fooks, Viji Venkataramanan, Kym M. Boycott, Francois P. Bernier, Roberto Mendoza-Londono, Taila Hartley, Robin Z. Hayeems and Deborah A. Marshall

Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA pp. 467-478

Jyotirmoy Sarker, Jeffrey A. Tice, David M. Rind and Surrey M. Walton

Cost-Utility Analysis of Genomic Profiling in Directing Targeted Therapy in Advanced NSCLC in Thailand pp. 479-491

Saowalak Turongkaravee, Surakit Nathisuwan, Thanyanan Baisamut and Jennis Meanwatthana

Australian Preferences for Prenatal Screening: A Discrete Choice Experiment Comparing Metropolitan and Rural/Regional Areas pp. 493-506

Amber Salisbury, Sarah Norris, Alison Pearce and Kirsten Howard

Exploratory Cost-Utility Analysis of a 37-Gene Panel Versus Usual Care to Guide Therapy for Patients with Intermediate-Risk Myeloid Malignancies pp. 507-517

Daniel Lindsay, Andrea Henden, Ricky Nelles, Thomas M. Elliott and Louisa G. Collins

Genetic Test Utilization and Cost among Families of Children Evaluated for Genetic Conditions: An Analysis of USA Commercial Claims Data pp. 519-530

Hadley Stevens Smith, Matthew Lakoma, Madison R. Hickingbotham, Dawn Cardeiro, Katharine P. Callahan, Monica H. Wojcik, Ann Chen Wu and Christine Y. Lu

Volume 23, issue 2, 2025

Health Economic Evaluations of Obesity Interventions: Expert Views on How We Can Identify, Interpret, Analyse and Translate Effects pp. 161-169

Samira B. Jabakhanji, Gintare Valentelyte, Fabian Manke-Reimers, Vidar Halsteinli, Rønnaug Ødegård, Adam Martin, Grace O’Malley, Jan Sorensen and Emilia Hagman

Value is Gendered: The Need for Sex and Gender Considerations in Health Economic Evaluations pp. 171-181

Martina Mchenga, Lavanya Vijayasingham, Rajalakshmi RamPrakash and Michelle Remme

Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach pp. 183-195

Michiel Zietse, Shannon L. Zeeuw, Anne-Sophie Klein Gebbink, Annemarie C. Vries, Marie-Rose B. S. Crombag, Roelof W. F. Leeuwen and Maaike J. Hoedemakers

Methods and Practical Considerations for Conducting Budget Impact Analysis for Non-Pharmaceutical Interventions pp. 197-208

Xuanqian Xie, Jennifer Guo, Alexis K. Schaink, Kamilla Guliyeva, Chunmei Li and Wendy J. Ungar

Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases pp. 209-229

Constanza Vargas, Richard Abreu Lourenco, Manuel Espinoza and Stephen Goodall

Productivity Losses due to Health Problems Arising from COVID-19 Pandemic: A Systematic Review of Population-Level Studies Worldwide pp. 231-251

Paweł Niewiadomski, Marta Ortega-Ortega and Błażej Łyszczarz

The Gift of Time, How Do I Want to Spend It? Exploring Preferences for Time Allocation Among Women with and without a Breast Cancer Diagnosis pp. 253-264

Ni Gao, Mandy Ryan, Suzanne Robinson and Richard Norman

Cost of Carbon in the Total Cost of a Healthcare Procedure: Example of Micro-Costing Study in a French Setting pp. 265-275

Paul-Simon Pugliesi, Hervé Frick, Stéphanie Guillot, Karine Ferrare, Catherine Renzullo, Alexandre Benoist, Serge Ribes, Guillaume Beltramo, Thomas Maldiney, Romain Schiphorst, Caroline Abdul Malak, Adrien Bevand, Laurie Marrauld and Catherine Lejeune

Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis pp. 277-290

Sarayuth Khuntha, Juthamas Prawjaeng, Kunnatee Ponragdee, Oranee Sanmaneechai, Varalak Srinonprasert and Pattara Leelahavarong

Quality-Adjusted Life Expectancy Norms Based on the EQ-5D-5L and SF-6Dv2 for China pp. 291-310

Shitong Xie, Xiaoning He, Weihua Guo and Jing Wu

Contextual Factors that Influence Antibiotic Prescribing: A Discrete Choice Experiment of GP Registrars pp. 311-317

Gregory Merlo, Lisa Hall, Parker Magin, Amanda Tapley, Katie J. Mulquiney, Alison Fielding, Andrew Davey, Joshua Davies and Mieke Driel

Assessing the Direct Impact of Death on Discrete Choice Experiment Utilities pp. 319-327

Hossein Ameri and Thomas G. Poder

Correction: Economic Evaluations of Robotic-Assisted Surgery: Methods, Challenges and Opportunities pp. 329-329

Tzu-Jung Lai, Robert Heggie, Hanin-Farhana Kamaruzaman, Janet Bouttell and Kathleen Boyd

Volume 23, issue 1, 2025

Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England pp. 5-17

Beth Woods, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Sue Harnan, Jean Hamilton, Alison Scope, Shijie Ren, Laura Bojke, Mark Wilcox, William Hope, Colm Leonard, Philip Howard, David Jenkins, Alan Ashworth, Andrew Bentley and Mark Sculpher

The Short Form 6 Dimensions (SF-6D): Development and Evolution pp. 19-33

Clara Mukuria, Donna Rowen, Brendan Mulhern, Emily McDool, Samer Kharroubi, Jakob B. Bjorner and John E. Brazier

Economic Evaluations of Robotic-Assisted Surgery: Methods, Challenges and Opportunities pp. 35-49

Tzu-Jung Lai, Robert Heggie, Hanin-Farhana Kamaruzaman, Janet Bouttell and Kathleen Boyd

Cost-Effectiveness of Perinatal Depression Screening: A Scoping Review pp. 51-64

Xinyue Xie, Sihan Lin, Yi Xia and Di Liang

Measures of Performance and Clinical Superiority Thresholds for ‘Test-and-treat’ Predictive Biomarkers pp. 65-74

Neil Hawkins, Janet Bouttell and Dmitry Ponomarev

Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold pp. 75-83

Melanie D. Whittington and T. Joseph Mattingly

Estimated Carbon Savings from Changing Surgical Trends in Primary Elective Total Hip Arthroplasty in England: A Retrospective Observational Study pp. 85-92

Jacob Koris, Elizabeth Ojelade, Hasina Begum, Maria Van-Hove, Tim W. R. Briggs and William K. Gray

Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania pp. 93-104

Amisa Tindamanyile Chamani, Bjarne Robberstad and Amani Thomas Mori

Comparison of Caregiver and General Population Preferences for Dependency-Related Health States pp. 105-117

Eva Rodríguez-Míguez and Antonio Sampayo

Measuring the Impact of Medical Cannabis Law Adoption on Employer-Sponsored Health Insurance Costs: A Difference-in-Difference Analysis, 2003–2022 pp. 119-129

Mitchell L. Doucette, Dipak Hemraj, Emily Fisher and D. Luke Macfarlan

The Impact of the Approach to Accounting for Age and Sex in Economic Models on Predicted Quality-Adjusted Life-Years pp. 131-140

Dawn Lee, Rose Hart, Darren Burns and Grant McCarthy

Social Costs of Smoking in the Czech Republic pp. 141-153

Petra Landovská

Balancing Economic and Social Cost and Environmental Sustainability: A Case Study of Reusable Isolation Gowns pp. 155-159

Niki Dunbar, Mike Forrester, Rebecca Patrick, Urvi Thanekar and Jaithri Ananthapavan